References reviewed but not cited

Papers reviewed by COPD Evaluation Committee but not cited
Abstracts reviewed by COPD Evaluation Committee but not cited

Papers reviewed by COPD Evaluation Committee but not cited

1.	Albers M, Schermer T, Heijdra Y, Molema J, Akkermans R, van Weel C. Predictive value of lung function below the normal range and respiratory symptoms for progression of chronic obstructive pulmonary disease. Thorax. 2008 Mar;63(3):201-7. Epub 2007 Sep 28
2.	Allegra L, Grassi C et al. Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. Ital J Chest Dis 1991;45:138-148
3.	Andrews R, Lynch M. Heliox in the treatment of chronic obstructive pulmonary disease. Emergency Medicine Journal 2004; 21(6): 670-675
4.	Appleton S, Poole P, Smith B, Cates C, Veale A, Bara A. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. The Cochrane Database of Systematic Reviews 2001, Issue 4. Art No.: CD001104. DOI:10.1002/14651858.CD001104
5.	Ashworth NL, Chad KE, Harrison EL, Reeder BA, Marshall SC. Home versus center based activity programs in older adults. The Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD004017.pub2. DOI: 10.1002/14651858:CD004017.pub2
6.	Austin M, Wood-Baker R. Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3 John Wiley & Sons, Ltd Chichester UK DOI: 10.1002/14651858.CD005534.pub2
7.	Austin M, Wood-Baker R,  Oxygen therapy in the pre-hospital setting for people suffering from an acute exacerbation of chronic obstructive pulmonary disease.  The Cochrane Database of Systematic Reviews: Protocols 2005 Issue 4. John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD005534
8.	Bahadori K, FitzGerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation--systematic review. Int J Chron Obstruct Pulmon Dis. 2007;2(3):241-51
9.	Bartolomeo N, Trerotoli P, Moretti A, Serio G. A Markov model to evaluate hospital readmission. BMC Medical Research Methodology 2008, 8:23 doi:10.1186/1471-2288-8-23 (provisional Pdf)
10.	Baselli LM, Oswald MA, Nashelsky JM.  Clinical inquiries. Do beta-blockers worsen respiratory status for patients with COPD?  J Fam Pract 2005 May;54(5): 472-3
11.	Bednarek M, Gorecka D, Wielgomas J, Czajkowska-Malinowska M, Regula J, Mieszko-Filipczyk G, Jasionowicz M, Bijata-Bronisz R, Lempicka-Jastrzebska M, Czajkowski M, Przybylski G, Zielinski J. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006;61:869-873
12.	Beeh KM, Kornmann O, Beier J, Ksoll, M, Buhl R. Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respiratory Medicine 2004;98:591-7
13.	Bize R, Burnand B, Mueller Y, Cornuz J. Effectiveness of biomedical risk assessment as an aid for smoking cessation: a systematic review. Tob Control. 2007 Jun;16(3):151-6
14.	Booker R. Chronic obstructive pulmonary disease and the NICE guideline. Nurs Stand. 2005 Feb 9-15;19(22): 43-52
15.	Borrill ZL, Houghton CM, Tal-Singer R, Vessey SR, Faiferman I, Langley SJ, Singh D. The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol. 2008 Feb;65(2):244-52
16.	Bourbeau J. Disease-specific self-management programs in patients with advanced chronic obstructive pulmonary disease: a comprehensive and critical evaluation. Disease Management and Health Outcomes 2003;11(5):311-319
17.	Bourbeau J, Collet JP, Schwartzman K, Ducruet T, Nault D, Bradley C. Economic benefits of self-management education in COPD. Chest. 2006 Dec;130(6):1704-11
18.	Bourdin A, Serre I, Flamme H, Vic P, Neveu D, Aubas P, Godard P, Chanez P. Can endobronchial biopsy analysis be recommended to discriminate between asthma and COPD in routine practice? Thorax 2004;59:488-493
19.	British Thoracic Society Guideline. Intermediate-care: Hospital-at-Home in chronic obstructive pulmonary disease. Thorax 2007;62(3):200-210
20.	Brown, CD, McCrory D, White J. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews: Reviews 2001 Issue 1 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD002984
21.	Brown CD, Fessler HE. Lung volume reduction surgery. COPD 2005;2(3):363-75
22.	Brown CD, McCrory D, White J. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD002984. DOI: 10.1002/14651858:CD002984
23.	Brutsche MH, Grossman P, Müller RE, Wiegand J, Pello, Baty F, Ruch W. Impact of laughter on air trapping in severe chronic obstructive lung disease. Int J Chron Obstruct Pulmon Dis. 2008;3(1):185-92
24.	Cazzola M, Ando F, Santus P, Rugger P, Di Marco F, Sanduzzi A, D'Amato M. A pilot study to assess the effects of combining fluticasone propionate/ salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD Pulmonary Pharmacology & Therapeutics 20 (2007) 556-561
25.	Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, Matera MG, Centanni S. Bronchodilator effect of an inhaled combination therapy with salmeterol & fluticasone and formoterol & budesonide in patients with COPD. 2003;97:453-7
26.	Cazzola M, Santus P, Di Marco F, Carlucci P, Mondoni M, Matera MG, Centanni S. Onset of action of formoterol/ budesonide in single inhaler vs. formoterol in patients with COPD. 2004;17:121-125
27.	Chhabra SK, Vijayan VK, Vasu T. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2006;48(2):97-102
28.	Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James W-Y, Wedzicha JA, Feder GS, Griffiths CJ. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial Respiratory Research 2007 8:93
29.	Colebourn CL, Barber V, Young JD. Use of helium-oxygen mixture in adult patients presenting with exacerbations of asthma and chronic obstructive pulmonary disease: a systematic review. Anaesthesia 2007;62(1):34-42
30.	Cooper CB & Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005; 330: 640-4
31.	Corrao G et al. Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. J Clin Epidemiol. 2005 Jan;58(1):92-7
32.	Daubin C et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study BMC Infectious Diseases 2008, 8:145
33.	Decramer, Marc and Ferguson, Gary. Clinical Safety of Long-Acting â2-Agonist and Inhaled Corticosteroid Combination Therapy in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease,2006 3:3, 163-171
34.	de Torres JP, Casanova C, Hernandez C, Abreu J, Montejo de Garcini A, Aguirre-Jaime A, Celli BR. Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health and Quality of Life Outcomes 2006;4:72
35.	Devine EC, Pearcy J. Meta-analysis of the effects of psychoeducational care in adults with chronic obstructive pulmonary disease. Patient Education & Counseling. 1996;29(2):167-78
36.	Diahn-Warng Perng,Cheng-Che WU, Kang-Cheng Su, Yu-Chin Lee, Reury-Perng Perng, Chi-Wei Tao. Additive benefits of tiotropium in COPD patients treated with long-acting b2 agonists and corticosteroids. Respirology (2006) 11, 598-602
37.	Dimopoulos G, Siempo II, Korbila IP, Manta KG, Falagas ME. Comparison of First-Line With Second-Line Antibiotics for Acute Exacerbations of Chronic Bronchitis: A Metaanalysis of Randomized Controlled Trials. Chest 2007; 132:447-455
38.	Dolmage TE and Goldstein RS. Effects of One-Legged Exercise Training of Patients With COPD Chest 2008; 133:370-376
39.	Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Beta-blocker use and the risk of death in hospitalized patients with acute exacerbations of COPD. Thorax. Published Online First: 19 October 2007. doi:10.1136/thx.2007.081893
40.	Esteban A, Frutos-Vivar F, Ferguson ND, Arabi Y, Apezteguia C, Gonzalez M, Epstein SK, Hill NS, Nava S, Soares M-A, D'Empaire G, Alia I, Anzueto A. Noninvasive positive-pressure ventilation for respiratory failure after extubation. The New England Journal of Medicine 2004; 350: 2452-2460
41.	Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19(3):189-99
42.	Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care - the SPiRiva Usual CarE (SPRUCE) study. Respiratory Research 2007, 8:45
43.	Gan WQ, Man SFP, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulmonary Medicine 2005;5:3 doi:10.1186/1471-2466-5-3
44.	Garrod R, Lasserson T. Role of physiotherapy in the management of chronic lung diseases: an overview of systematic reviews. Respir Med. 2007 Dec;101(12):2429-36. Epub 2007 Sep 17
45.	Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. Respirology. 2005 Jan;10(1):9-17
46.	Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax. 2007 Nov;62(11):944-9. Epub 2007 May 25
47.	Greenstone M & Lasserson TJ. Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD000223. DOI: 10.1002/14651858:CD000223
48.	Groenewegen KH, Postma DS, Hop WC, Wielders PL, Schlösser NJ, Wouters EF; COSMIC Study Group. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008 Feb;133(2):350-7. Epub 2008 Jan 15
49.	Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E, Nieminen MM, Aine T, Bakke P, Janson C. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006 Aug 16;7:109
50.	Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist S, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28(3):523-32
51.	Harris et al. Providing patients with reviews of evidence about COPD treatments: A controlled trial of outcomes. Chronic Respiratory Disease 2006;3:133-140
52.	Harris M, Smith B, Veale A. Engaging patients in evidence-based medicine: development of a resource for people with chronic obstructive pulmonary disease. Chronic Illn 2005;1(4):330-6
53.	Harvey PA et al. Implementing evidence-based guidelines: inpatient management of chronic obstructive pulmonary disease. Intern Med J. 2005 Mar;35(3):151-5
54.	Herland K et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med. 2005 Jan;99(1):11-19
55.	Hunninghake DB. Cardiovascular Disease in Chronic Obstructive Pulmonary Disease. Proc Am Thoracic Soc 2005;2(1):44-9
56.	Husereau  D, Shukla V, Boucher M, Mensinkai S, Dales R. Long acting beta2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. BMC Pulm Med 2004;4:7
57.	International Primary Care Respiratory Group (IPCRG). The use  of long-acting beta2-agonists (LABAs) in asthma. IPCRG position statement following warnings from regulatory authorities including the US FDA. September 2006
58.	Jolliet P, Tassaux D, Roeseler J, Burdet L, Broccard A, D'Hoore W, Borst F, Reynaert M, Schaller M-D, Chevrolet J-C. Helium-oxygen versus air-oxygen non-invasive pressure support in decompensated chronic obstructive disease: A prospective multicenter study. Crit Care Med  2003; 31(3): 878-884
59.	Jones PW, Greenstone M. Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD002881. DOI: 10.1002/14651858:CD002881
60.	Jordan N, Lee TA, Valenstein M, Weiss KB. Effect of care setting on evidence-based depression treatment for veterans with COPD and comorbid depression. J Gen Intern Med. 2007 Oct;22(10):1447-52. Epub 2007 Aug 9
61.	Kahn LS, Fox CH, Olawaiye A, Servoss TJ, McLean-Plunkett E. Facilitating quality improvement in physician management of comorbid chronic disease in an urban minority practice. J Natl Med Assoc. 2007 Apr;99(4):377-83
62.	Karish SB, Gagnon JM. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Ann Pharmacother 2006;40(6):1096-104
63.	Keenan SP, Sinuff T, Cook DJ, Hill NS. Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from non-invasive positive-pressure ventilation? A systematic review of the literature. Ann Intern Med. 2003;138(11):861-70
64.	Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl CG, Partridge MR. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006 Jul;130(1):133-42
65.	Kida K, Wakabayashi R, Mizuuchi T, Murata A. Screening for suspected chronic obstructive pulmonary disease with an eleven-item pre-interview questionnaire (11-Q). Intern Med 2006;45(21):1201-7
66.	Kunik ME, Azzam PN, Souchek J, Cully JA, Wray NP, Krishnan LL, Nelson HA, Stanley MA. A practical screening tool for anxiety and depression in patients with chronic breathing disorders. Psychosomatics 2007 Jan-Feb;48(1):16-21
67.	Kunisaki KM, Rice KL, Niewoehner DE. Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence. Drugs Aging. 2007;24(4):303-24
68.	Lapperre TS,  Sont JK,  Schadewijk A, Gosman MME, Postma DS, Bajema IM, Timens W, Mauad T, Hiemstra PS and the GLUCOLD Study Group. Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respiratory Research 2007, 8:85 doi:10.1186/1465-9921-8-85
69.	Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008 Feb 15;101(4):530-5. Epub 2007 Dec 26
70.	Lin K, MD, Watkins B, Johnson T, Rodriguez JA and Barton MB. Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;148:535-543
71.	Lusuardi M, De Benedetto F, Paggiaro P, Sanguinetti CM, Brazzola G, Ferri P, Donner CF. A randomized controlled trial of office spirometry in asthma and COPD in standard general practice. Chest 2006;129(4):844-852
72.	Machado M-C L, Krishnan JA, Buist SA, Bilderback AL, Fazolo GP, Santarosa MG, Queiroga Jr. F, Vollmer WM. Sex differences in survival of oxygen-dependent patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2006;174:524-529
73.	Maltais F et al.  A Canadian, multicentre, randomized clinical trial of home-based pulmonary rehabilitation in chronic obstructive pulmonary disease: rationale and methods.  Can Resp J. 2005 May-Jun;12(4): 193-8
74.	Martina SD, Ismail MS, Vesta KS. Cilomilast: orally active selected phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2006;40(10):1822-8
75.	McCrory DC, Brown C, Gelfand SE, Bach PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119(4):1190-29
76.	McNicholas WT, Calverley PMA, Lee A, Edwards JC on behalf of the Tiotropium Sleep Study in COPD Investigators. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD Eur Respir J 2004; 23:825-831
77.	Monninkhof EM, van der valk PDLPM, van der Palen J, van Herwaarden CLA, Partridge MR, Waters EH, Zielhuis GA. Self-management education for chronic obstructive pulmonary disease The Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD002990. DOI: 10.1002/14651858:CD002990.
78.	Mucha L, Stephenson J, Morandi N, Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. Gend Med. 2006 Dec;3(4):279-91
79.	Nathell L, Nathell M, Malmberg P, Larsson K. COPD diagnosis related to different guidelines and spirometry techniques. Respiratory Research 2007 8:89
80.	Niederman MS, Anzueto A, Sethi S, Choudhri S, Kureishi A, Haverstock D, Perroncel R. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med. 2006 Oct;100(10):1781-90. Epub 2006 Mar 13
81.	Niesink A, Trappenburg JC, de Weert-van Oene GH, Lammers JW, Verheij TJ, Schrijvers AJ. Systematic review of the effects of chronic disease management on quality-of-life in people with chronic obstructive pulmonary disease (Provisional record). Respiratory Medicine 2007; 101(11): 2233-2239
82.	O'Brien, K., Geddes EL, Reid, WD, Brooks, D., Crowe, J. Inspiratory muscle training compared with other rehabilitation interventions in chronic obstructive pulmonary disease:  systemic review update. Journal of Cardiopulmonary Rehabilitation and Prevention 2008, 28:128-141.
83.	O'Donnell DE, Hernandez P, Aaron S, Bourbeau J, Marciniuk D, Hodder R, Balter M, Ford G, Gervais A, Goldstein R, Maltais F, Road J, McKay V, Schenkel J. Canadian Thoracic Society COPD Guidelines: Summary of highlights for family doctors. Can Respir J 2003;10(4):183-185
84.	Ofir D, Laveneziana P, Webb KA, Lam Y-M, O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage 1 chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:622-62
85.	Oh H, Seo W. Meta-analysis of the effects of respiratory rehabilitation programmes on exercise capacity in accordance with programme characteristics. J Clin Nurs. 2007 Jan;16(1):3-15
86.	Oostenbrink JB et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health. 2005 Jan-Feb;8(1):32-46
87.	Paz-Diaz H, Montes de Oca M, Lopez JM, Celli BR. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil. 2007 Jan;86(1):30-6
88.	Price LC, Lowe D, Hosker HS, Anstey K, Pearson MG, Roberts CM; British Thoracic Society and the Royal College of Physicians Clinical Effectiveness Evaluation Unit (CEEu). UK National COPD Audit 2003: Impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax 2006 Oct;61(10):837-42
89.	Price DB, Tinkelman DG, Halbert RJ, Nordyke RJ, Isonaka S, Nonikov D, Juniper EF, Freeman D, Hausen T, Levy ML, Ostrem A, van der Molen T, van Schayck CP. Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006;73(3):285-95
90.	Puhan MA et al. How should COPD patients exercise during respiratory rehabilitation? Comparison of exercise modalities and intensities to treat skeletal muscle dysfunction. Thorax. 2005 May;60(5): 367-75
91.	Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: A systematic review and metaanalysis. Chest 2008;133:756-766
92.	Ram FS et al.  Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2005 Feb;99(2):135-44
93.	Ram FSF, Brocklebank DM, Muers M, Wright J, Jones PW.  Pressurised metered-dose inhalers versus all other hand-held inhaler devices to deliver bronchodilators for chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews: Reviews 2002 Issue 1 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD002170
94.	Ram FS. Use of theophylline in chronic obstructive pulmonary disease: examining the evidence. Curr Opin Pulm Med 2006;12(2):132-9
95.	Ramsey SD, Shroyer AL, Sullivan SD, Wood DE. Updated evaluation of the cost-effectiveness of lung volume reduction surgery. Chest 2007 Mar;131(3):823-32
96.	Ranes J and Stoller JK. A review of alpha-1 antitrypsin deficiency. Seminars in Respiratory and Critical Care Medicine 2005;26(2):154-166
97.	Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Morii H, Devogelaer J-P, Peel N, Haim M, Bruyere O, Reginster J-Y. Inhaled corticosteroid effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporosis Int. 2003;14:179-190
98.	Ringbaek TJ. Home oxygen therapy in COPD patients. Results from the Danish Oxygen register. Dan Med Bull. 2006;53(3):310-25
99.	Rodrigo G, Pollack C, Rodrigo C, Rowe B, Walters EH. Heliox for treatment of exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD003571. DOI: 10.1002/14651858.CD003571
100.	Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008 May;133(5):1079-87
101.	Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther. 2007;20(5):495-502. Epub 2006 Mar 2
102.	Rodríguez-Roisin R. COPD exacerbations • 5: Management. Thorax 2006;61;535-544
103.	Rootmensen GN, van Keimpema AR, Looysen EE, van der Schaaf L, de Haan RJ, Jansen HM. The effects of additional care by a pulmonary nurse for asthma and COPD patients at a respiratory outpatient clinic: results from a double blind, randomized clinical trial. Patient Educ Couns. 2008 Feb;70(2):179-86. Epub 2007 Nov 26
104.	Rose C, Wallace L, Dickson R, Ayres J, Lehman R, Searle Y, Burge PS. The most effective psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive pulmonary disease (COPD): a systematic review. Patient Education and Counseling 2002;47(4):311-318
105.	Salman GF, Mosier MC, Beasley BW, Calkins DR. Rehabilitation for patients with Chronic Obstructive Pulmonary Disease: Meta-analysis of Randomized Controlled Trials. J Gen Intern Med 2003; 18: 213-221
106.	Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD003566. DOI:10.1002/14651858.CD003566.pub2
107.	Salpeter SR, Buckley NS. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol 2006;31(2-3):219-30
108.	Schenkein JG, Nahm MH, Dransfield MT. Pneumococcal Vaccination for Patients With COPD: Current Practice and Future Directions. Chest 2008;133:767-774
109.	Scher DL, Arsura EL. Multifocal atrial tachycardia: mechanisms, clinical correlates, and treatment. Am Heart J 1989 Sep;118(3):574-80
110.	Schermer TRJ & Quanjer PH. COPD screening in primary care: who is sick? Primary Care Respiratory Journal 2007;16(1):49-53
111.	Schuetz P, Christ-Crain M, Schild U, Süess E, Facompre M, Baty F, Nusbaumer C, Brutsche M, Müller B. Effect of a 14-day course of systemic corticosteroids on the hypothalamicpituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease. BMC Pulmonary Medicine 2008, 8:1 doi:10.1186/1471-2466-8-1
112.	Schunemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ). COPD 2005;2(1):81-9
113.	Shea SD, Taylor NF, Paratz J. Peripheral muscle strength training in COPD: a systematic review. Chest 2004;126(3): 903-914
114.	Sin DD, McAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease. JAMA 2003;290(17):2301-2312
115.	Smith-Sivertsen T and Rortveit G. Should general practitioners screen smokers for COPD. Scand J Prim Health Care 2004;22:196-201
116.	Steurer-Stey C, Bachmann LM, Steurer J, Tramer MR. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 2004; 126(5): 1645-1655
117.	Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/ usual therapy: results of a meta-analysis. Respiratory Research 2006;7:147
118.	Strange et al. Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulmonary Medicine 2007, 7:10
119.	Sutherland E Rand. Inhaled steroids and outcomes in COPD: Progressing beyond FEV1. Chest 2007;131(3):648-649
120.	Tierney WM et al. Can computer-generated evidence-based care suggestions enhance evidence-based management of asthma and chronic obstructive pulmonary disease? A randomized, controlled trial. Health Serv Res. 2005 Apr;40(2): 477-97
121.	Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D, Juniper EF, Freeman D, Hausen T, Levy ML, Ostrem A, van der Molen T, van Schayck CP. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 2006;73(3):296-305
122.	University of York Cochrane Centre for Reviews, Dissemination. Inhaler devices for the management of asthma and COPD. Effective Health Care 2003;8(1):1-12
123.	Uronis HE, Currow DC, Abernethy AP. Palliative management of refractory dyspnea in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(3):289-304
124.	Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTAN study group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005;60(4):301-4
125.	Vestbo J, Soriano JB, Anderson JA, Calverley P, Pauwels R, Jones P, TRISTAN Study Group. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. 2004
126.	Vitry AI and Zhang Y. Quality of Australian clinical guidelines and relevance to the care of older people with multiple comorbid conditions. MJA 2008; 189: 360-365
127.	Walters JA, Hansen EC, Johns DP, Blizzard EL, Walters EH, Wood-Baker R. A mixed methods study to compare models of spirometry delivery in primary care for patients at risk of COPD. Thorax. 2008 May;63(5):408-14. Epub 2007 Nov 16
128.	Wedzicha JA, Seemungal TAR. Inhaled corticosteroids in COPD: a light at the end of the tunnel? Thorax 2005;60:977-978
129.	Wedzicha JA. Collaboration in inhaled steroids in COPD. Thorax 2005;60:977
130.	West R and Zhou X. Is nicotine replacement therapy for smoking cessation effective in the ‘‘real world''? Findings from a prospective multinational cohort study. Thorax 2007;62:998-1002
131.	Wijkstra PJ, Lacasse Y, Guyatt GH, Goldstein RS.  Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD002878. DOI: 10.1002/14651858:CD002878
132.	Wilson DH, Tucker G, Frith P, Appleton, S, Ruffin RE, Adams RJ. Trends in hospital admissions and mortality from asthma and chronic obstructive pulmonary disease in Australia 1993-2003. MJA 2007;186:408-411
133.	Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med. 2007 Nov 6;147(9):639-53
134.	Wood-Baker R, Walters J, Walters EH. Systemic corticosteroids in chronic obstructive pulmonary disease: an overview of Cochrane systematic reviews. Respir Med. 2007 Mar;101(3):371-7. Epub 2006 Sep 7
135.	Xuan W, Correll P, Ampon R, Williamson M, Marks G. Time trends in hospitalisations and deaths due to COPD and asthma among persons aged 55 and over, 1997-2003. Australian Centre for Asthma Monitoring & Woolcock Institute of Medical Research (Poster)
136.	Zwar N et al. A cluster randomised controlled trial of nurse and GP partnership for care of Chronic Obstructive Pulmonary Disease. BMC Pulmonary Medicine 2008, 8:8

 

Abstracts reviewed by COPD Evaluation Committee but not cited

1.	Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, Maltais F, Bourbeau JF, Goldstein RS, Balter M, O'Donnell D, Fitzgerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008 Feb;63(2):122-8. Epub 2007 Aug 16.
2.	Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis. 2007;2(4):535-40.
3.	Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006 Mar;61(3):189-95
4.	Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol 1991 Aug;31(8):714-8
5.	Anker SD, John M Pederson, Raguso C, Cicoira M, Dardai E, Laviano A, Ponikowski P, Schols AM; DGEM (German Society for Nutritional Medicine); Becker HF, Bohm M, Brunkhorst FM, Vogelmeier C; ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on enteral nutrition: Cardiology and pulmonology. Clin Nutr 2006;25(2):311-8
6.	Anonymous. Varenicline effective for smoking cessation. Journal of Family Practice 2006;55(10):848-849
7.	Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am J Med. 2006 Oct;119(10 Suppl 1):46-53.
8.	Anzueto A. Disease modification in chronic obstructive pulmonary disease. Clin Chest Med. 2007 Sep;28(3):609-16,vii.
9.	Arandjus C, Black PN, Poole PJ, Wood Baker R, Steurer-Stey C. Oral bacterial vaccines for the prevention of acute exacerbations in chronic obstructive pulmonary disease and chronic bronchitis. Respir Med. 2006 Oct;100(10):1671-81
10.	Aronow WS, Van Camp S, Turbow M, Whittaker K, Lurie M. Acebutolol in supraventricular arrhythmias. Clin Pharmacol Ther 1979 Feb;25(2):149-53
11.	Balser E, Neher JO, Safranek S, Taraday J. Clinical inquiries: When are antibiotics indicated for acute COPD exacerbations? J Fam Pract. 2006 Dec;55(12):1079-80
12.	Bansal V, Hill K, Dolmage TE, Brooks D, Woon LJ, Goldstein RS. Modifying track layout from straight to circular has a modest effect on the 6-min walk distance. Chest. 2008 May;133(5):1155-60. Epub 2008 Feb 8.
13.	Barakat S, Michele G, George P, Nicole V, Guy A. Outpatient pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(1):155-62.
14.	Baraldi E, Carraro S. Exercise testing and chronic lung diseases in children. Paediatr Respir Rev 2006;7 Suppl 1:S196-8
15.	Barreiro E, Schols AM, Polkey MI, Galdiz JB, Gosker HR, Swallow EB, Coronell C, Gea J; ENIGMA in COPD project. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax. 2008 Feb;63(2):100-7. Epub 2007 Sep 17.
16.	Bausewein C, Farquhar M, Booth S, Gysels M, Higginson IJ. Measurement of breathlessness in advanced disease: a systematic review. Respir Med. 2007 Mar;101(3):399-410. Epub 2006 Aug 17
17.	Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008 May;63(5):402-7. Epub 2008 Jan 30.
18.	Beeh KM, Beier J. Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma? Clin Exp Allergy 2006;36(2):142-157
19.	Bellamy D, Bouchard J, Henrischsen S, Johanssen G, Langhammer A, Reid J, van Weel C, Buist S. International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006;15(1):48-57
20.	Bhattaram VA, Bonapace C, Chilukuri DM, Duan JZ, Garnett C, Gobburu JV, Jang SH, Kenna L, Lesko LJ, Madabushi R, Men Y, Powell JR, Qiu W, Ramchandani RP, Tornoe CW, Wang Y, Zheng JJ. Impact of pharmacometric reviews on new drug approval and labeling decisions—a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther. 2007 Feb;81(2):213-21.
21.	Bradley J M, Lasserson T, Elborn S, MacMahon J, O'Neill B. A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD (Brief record). Chest 2007; 131(1): 278-285
22.	Braido F, Tarantini F, Ghiglione V, Melioli G, Canonica GW. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis. 2007;2(3):335-45.
23.	Brogger J, Steen VM, Eiken HG, Gulsvik A, Bakke P. Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. Eur Respir J 2006;27(4):682-8
24.	Brozek Jan, Akl Elie A, Jaeschke Roman, Terrenato Irene, Cilenti Vincenzo, Cazzola Mario , Fabbri Leonardo, O'Byrne Paul, Guyatt Gordon H, Schünemann Holger. Long-acting beta2-agonists for chronic obstructive pulmonary disease: serious adverse events. Cochrane Database of Systematic Reviews: Protocols 2008 Issue 3 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD007200
25.	Brubacher JR, Levine B, Hoffman RS. Intestinal pseudo-obstruction (Ogilvie's syndrome) in theophylline overdose. Vet Hum Toxicol 1996 Oct;38(5):368-70
26.	Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003 Jun;21(6):1012-6
27.	Bullen C, Whittaker R, McRobbie H, Fagerström K. A clinical imperative: assisting patients who smoke to reduce their risk of cardiovascular disease. Prev Cardiol. 2007 Spring;10(2 Suppl 1):5-9.
28.	Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev. 2007 Mar;12(1):23-36. Epub 2007 Mar 8
29.	Burstein AH, Clark DJ, O'Gorman M, Willavize SA, Brayman TG, Grover GS, Walsky RL, Obach RS, Faessel HM. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study. J Clin Pharmacol. 2007 Nov;47(11):1421-9.
30.	Burstein AH, Fullerton T, Clark DJ, Faessel HM. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol. 2006 Nov;46(11):1234-40.
31.	Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005353.
32.	Calverley PM, Scott S.  Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD. 2006 Dec;3(4):233-42
33.	Calvert LD, Shelley R, Singh SJ, Greenhaff PL, Bankart J, Morgan MD, Steiner MC. Dichloroacetate enhances performance and reduces blood lactate during maximal cycle exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 May 15;177(10):1090-4. Epub 2008 Feb 8.
34.	Candy B, Taylor SJ, Ramsay J, Esmond G, Griffiths CJ, Bryar RM. Service implications from a comparison of the evidence on the effectiveness and a survey of provision in England and Wales of COPD specialist nurse services in the community. Int J Nurs Stud. 2007 May;44(4):601-10. Epub 2006 Feb 28
35.	Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007 May;32(5):912-23. Epub 2006 Jul 27.
36.	Cappelleri JC, Baker CL, Bushmakin AG, Reeves K. Effect of varenicline on reinforcing effects associated with smoking (POS1-118). Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida 2006:70
37.	Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale. Curr Med Res Opin. 2005 May;21(5):749-60.
38.	Casanova C, Baudet JS, del Valle Velasco M, Martin JM, Aguirre-Jaime A, de Torres JP, Celli BR. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J 2004 Jun;23(6):841-5
39.	Cecins N, Geelhoed E, Jenkins SC. Reduction in hospitalisation following pulmonary rehabilitation in patients with COPD. Aust Health Rev. 2008 Aug;32(3):415-22.
40.	Celli BR. Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thoracic Soc 2006;3(1):58-65
41.	Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8. Epub 2008 May 29.
42.	Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2007 Apr 18(2):CD006316
43.	Chen YH, Yao WZ, Cai BQ, Wang H, Deng XM, Gao HL, Huang JS, Wang XM. Economic analysis in admitted patients with acute exacerbation of chronic obstructive pulmonary disease. Chin Med J (Engl). 2008 Apr 5;121(7):587-91.
44.	Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005 May 19;48(10):3474-7.
45.	Cofta-Woerpel L, Wright KL, Wetter DW. Smoking cessation 1: pharmacological treatments. Behav Med. 2006 Summer;32(2):47-56.
46.	Cofta-Woerpel L, Wright KL, Wetter DW. Smoking cessation 3: multicomponent interventions. Behav Med. 2007 Winter;32(4):135-49.
47.	Cohen L, Kitzes R, Shnaider H. Multifocal atrial tachycardia responsive to parenteral magnesium. Magnes Res 1988 Dec;1(3-4):239-42
48.	Corelli RL, Hudmon KS. Pharmacologic interventions for smoking cessation. Crit Care Nurs Clin North Am. 2006 Mar;18(1):39-51, xii.
49.	Cornuz J. Smoking cessation interventions in clinical practice. Eur J Vasc Endovasc Surg. 2007 Oct;34(4):397-404. Epub 2007 Aug 3.
50.	Cornuz J. Treating tobacco use and dependence in clinical practice. Expert Opin Pharmacother. 2006 Apr;7(6):783-92.
51.	Coventry PA, Hind D. Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: Systematic review and meta-analysis. J Psychosom Res. 2007 Nov;63(5):551-65.
52.	Coxson HO, Quiney B, Sin DD, Xing L, McWilliams AM, Mayo JR, Lam S. Airway wall thickness assessed using computed tomography and optical coherence tomography. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1201-6. Epub 2008 Feb 28.
53.	Cranston JM, Crockett AJ, Moss JR, Pegram RW, Stocks NP. Models of chronic disease management in primary care for patients with mild-to-moderate asthma or COPD: a narrative review. Med J Aust. 2008 Apr 21;188(8 Suppl):S50-2.
54.	Criner GJ, Sharafkhaneh A, Player R, Conoscenti CS, Johnson P, Keyser MT, Cassino C. Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. COPD. 2008 Feb;5(1):35-41.
55.	Crockett A J, Cranston J M, Moss J R, Alpers J H. A review of long-term oxygen therapy for chronic obstructive pulmonary disease (Brief record). Respiratory Medicine 2001; 95(6): 437-443
56.	Croghan E. Optimizing on smoke free legislation making the most of the opportunity. Br J Community Nurs. 2007 Aug;12(8):334-6.
57.	Cummings KM, Mahoney M. Current and emerging treatment approaches for tobacco dependence. Curr Oncol Rep. 2006 Nov;8(6):475-83.
58.	Curtis JR, Cook DJ, Sinuff T, White DB, Hill N, Keenan SP, Benditt JO, Kacmarek R, Kirchhoff KT, Levy MM; Society of Critical Care Medicine Palliative Noninvasive Positive VentilationTask Force. Noninvasive positive pressure ventilation in critical and palliative care settings: understanding the goals of therapy. Crit Care Med. 2007 Mar;35(3):932-9
59.	D’Souza AO, Smith MJ, Miller LJ, Kavookjian J. An appraisal of pharmacoeconomic evidence of maintenance therapy in COPD. Chest 2006;129(6):1693-708
60.	deRuiter W, Faulkner G. Tobacco harm reduction strategies: the case for physical activity. Nicotine Tob Res. 2006 Apr;8(2):157-68.
61.	Doggrell SA. Which is the best primary medication for long-term smoking cessation—nicotine replacement therapy, bupropion or varenicline? Expert Opin Pharmacother. 2007 Dec;8(17):2903-15.
62.	Dolmage TE, Goldstein RS. Effects of one-legged exercise training of patients with COPD. Chest. 2008 Feb;133(2):370-6. Epub 2007 Oct 9.
63.	Donner CF. Acute exacerbation of chronic bronchitis: need for an evidence-based approach. Pulm Pharmacol Ther. 2006;19 Suppl 1:4-10. Epub 2005 Dec 15
64.	Duck A. Cost-effectiveness and efficacy in long-term oxygen therapy. Nurs Times. 2006 Feb 14-20;102(7):46-50
65.	Durham L, Hancock HC. Critical care outreach 2: uncovering the underpinning philosophy and knowledge through collaborative reflection. Nurs Crit Care. 2006 Sep-Oct;11(5):248-59
66.	Eastham KM, Hammal DM, Parker L, Spencer DA. A follow-up study of children hospitalised with community-acquired pneumonia. Arch Dis Child. 2008 Sep;93(9):755-9. Epub 2008 Apr 1.
67.	Ebbert JO, Sood A, Hays JT, Dale LC, Hurt RD. Treating tobacco dependence: review of the best and latest treatment options. J Thorac Oncol. 2007 Mar;2(3):249-56.
68.	Eisner MD, Blanc PD, Yelin EH, Sidney S, Katz PP, Ackerson L, Lathon P, Tolstykh I, Omachi T, Byl N, Iribarren C. COPD as a systemic disease: impact on physical functional limitations. Am J Med. 2008 Sep;121(9):789-96.
69.	Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control. 2006 Aug;15(4):280-5.
70.	Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol. 2006 Dec;46(12):1439-48.
71.	Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol. 2006 Sep;46(9):991-8.
72.	The FDA approves new drug for smoking cessation. FDA Consum. 2006 Jul-Aug;40(4):29.
73.	Ferreira I M, Brooks D, Lacasse Y, Goldstein R S. Nutritional intervention in COPD: a systematic overview (Brief record). Chest 2001; 119(2): 353-363
74.	Ferreira I M, Brooks D, Lacasse Y, Goldstein R S. Nutritional support for individuals with COPD: a meta-analysis (Brief record). Chest 2000; 117(3): 672-678
75.	Foreman MG, Willsie SK. Health care disparities in critical illness. Clin Chest Med. 2006 Sep;27(3):473-86, vii
76.	Foronjy R, Wallace A, D'Armiento J. The pharmokinetic limitations of antioxidant treatment for COPD. Pulm Pharmacol Ther. 2008;21(2):370-9. Epub 2007 Oct 23.
77.	Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006 May;60(5):571-6.
78.	Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res 2006;7:74
79.	Frey U, Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet. 2008 Sep 20;372(9643):1088-99.
80.	Frishman WH, Mitta W, Kupersmith A, Ky T. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol Rev. 2006 Mar-Apr;14(2):57-73.
81.	Frishman WH. Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations. Prev Cardiol. 2007 Spring;10(2 Suppl 1):10-22.
82.	Fromer L, Cooper CB. A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD. Int J Clin Pract. 2008 Aug;62(8):1219-36. Epub 2008 Jun 28.
83.	Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4(3):253-62
84.	Garwood CL, Potts LA. Emerging pharmacotherapies for smoking cessation. Am J Health Syst Pharm. 2007 Aug 15;64(16):1693-8.
85.	Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006 Mar;15(3):307-15.
86.	Giudici MC, Gumpert TJ, Heathman LL. Narrow-complex tachycardia. Am Fam Physician 1994 Mar;49(4):823-34
87.	Glover ED, Rath JM. Varenicline: progress in smoking cessation treatment. Expert Opin Pharmacother. 2007 Aug;8(11):1757-67.
88.	Gonzales DH, Rennard SI, Billing CB, Reeves KR, Watsky E, Gong J. A pooled analysis of varenicline, and alpha 4 beta 2 nicotinic receptor partial agonist vs bupropion for smoking cessation (PA9-2). Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida 2006:32
89.	Gonzales D, Swartz S, Oncken C, Wang H, Reeves K, Gong J, Watsky E, Williams K. Quitting patterns during 12 weeks of treatment for smoking cessation with varenicline: results from a pooled-analysis of varenicline vs bupropion or placebo (PA11-2). Society for Research on Nicotine and Tobacco 13th Annual Meeting February 21-24, Austin, Texas 2007: 32
90.	Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA : the journal of the American Medical Association 2006; 296(1):47-55
91.	Granizo JJ, Gimenez MJ, Barberan J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther. 2006 Dec;28(12):2061-9
92.	Grgic A, Wilkens H, Kubale R, Gröschel A, Buecker A, Sybrecht GW. Low-dose MDCT for surveillance of patients with severe homogeneous emphysema after bronchoscopic airway bypass. AJR Am J Roentgenol. 2008 Sep;191(3):W112-9.
93.	Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, Bethke TD, Hiemstra PS, Rabe KF. The PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax. 2007 Jun 15; [Epub ahead of print]
94.	Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of COPD: a systematic review. Eur Respir J 2006;28(2):330-8
95.	Halbert RJ, Isonaka S. International Primary Care Respiratory Group (IPCRG) Guidelines: integrating diagnostic guidelines for managing chronic respiratory diseases in primary care.  Prim Care Respir J 2006;15(1):13-19
96.	Hallberg J, Dominicus A, Eriksson UK, Gerhardsson de Verdier M, Pedersen NL, Dahlbäck M, Nihlén U, Higenbottam T, Svartengren M. Interaction between smoking and genetic factors in the development of chronic bronchitis. Am J Respir Crit Care Med. 2008 Mar 1;177(5):486-90. Epub 2007 Nov 29.
97.	Hanania NA. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther. 2007 Oct;29(10):2121-33.
98.	Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008 Feb;5(1):25-34.
99.	Harris M, Smith B, Veale A, Esterman A, Frith P, Selim P. Informed consumers as drivers of evidence based medicine: a trial. X111 International Cochrane Colloquium. October 2005, Melbourne. (Oral presentation) http://www.imbi.uni-freiburg.de/OJS/cca/index.php/cca/article/view/1205
100.	Harris M, Wildgoose D, Veale A, Smith B. Patient mediated interventions to increase adoption of evidence: aids and barriers to an intervention in chronic obstructive pulmonary disease (COPD). X111 International Cochrane Colloquium. October 2005, Melbourne. (Oral presentation) http://www.imbi.uni-freiburg.de/OJS/cca/index.php/cca/article/view/1206
101.	Hasanoglu HC, Yildirim Z, Hasanoglu A, Ozcan C, Gokirmak M, Koksal N, Kalkan S. Effects of ranitidine on pulmonary function tests of patients with chronic obstructive pulmonary disease. Pharmacol Res 2003 Jun;47(6):535-9
102.	Hill K, Jenkins SC, Cecins N, Philippe DL, Hillman DR, Eastwood PR. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008 Sep;89(9):1782-7.
103.	Hurford WE, Cheifetz IM. Respiratory controversies in the critical care setting. Should heliox be used for mechanically ventilated patients? Respir Care. 2007 May;52(5):582-91; discussion 591-4
104.	Hughes JR. Measurement of the effects of abstinence from tobacco: a qualitative review. Psychol Addict Behav. 2007 Jun;21(2):127-37.
105.	Incorvaia C, Riario-Sforza GG, Pravettoni C, Yacoub MR, Frati F. Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium. Int J Chron Obstruct Pulmon Dis. 2008;3(1):123-6.
106.	Jackson KC 2nd, Nahoopii R, Said Q, Dirani R, Brixner D. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J Occup Environ Med. 2007 Apr;49(4):453-60
107.	Jarvis H. Exploring the evidence base of the use of non-invasive ventilation. Br J Nurs. 2006 Jul 27-Aug 9;15(14):756-9
108.	Jónsdóttir H. Nursing care in the chronic phase of COPD: a call for innovative disciplinary research. J Clin Nurs. 2008 Apr;17(7B):272-90.
109.	Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):56-63.
110.	Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007 Mar-Apr;29(2):147-55
111.	Kawayama T, Hoshino T, Ichiki M, Tsuda T, Kinoshita M, Takata S, Koga T, Iwanaga T, Aizawa H; Kurume COPD Study Group. Effect of add-on therapy of tiotropium in COPD treated with theophylline. Int J Chron Obstruct Pulmon Dis. 2008;3(1):137-47.
112.	Keating RJ, Gersh BJ, Hodge DO, Weivoda PL, Patel PJ, Hammill SC, Shen WK. Effect of atrial fibrillation pattern on survival in a community-based cohort. Am J Cardiol 2005 Nov 15;96(10):1420-4
113.	Keating GM, Siddiqui MA. Varenicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs. 2006;20(11):945-60
114.	Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis. 2008;3(1):127-36.
115.	Kolodziej MA, Jensen L, Rowe B, Sin D. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J. 2007 Aug;30(2):293-306. Epub 2007 Apr 25
116.	Koretz RL, Avenell A, Lipman TO, Braunschweig CL, Milne AC. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol. 2007 Feb;102(2):412-29; quiz 468
117.	Kothari SA, Apiyasawat S, Asad N, Spodick DH. Evidence supporting a new rate threshold for multifocal atrial tachycardia. Clin Cardiol 2005 Dec;28(12):561-3
118.	Kumar D, Saksena RK. Best evidence topic report. Use of Heliox in the management of acute exacerbation of COPD. Emerg Med J. 2007 Jan;24(1):45-8
119.	Kuralay E, Cingoz F, Kilic S, Bolcal C, Gunay C, Demirkilic U, Tatar H. Supraventricular tachyarrythmia prophylaxis after coronary artery surgery in chronic obstructive pulmonary disease patients (early amiodarone prophylaxis trial). Eur J Cardiothorac Surg 2004 Feb;25(2):224-30
120.	Lacasse Y, Martin S, Lasserson TJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease: a Cochrane systematic review (Brief record). Europa Medicophysica 2007;43(4):475-485
121.	Lam CY, Minnix JA, Robinson JD, Cinciripini PM. A brief review of pharmacotherapies for smoking cessation. J Natl Compr Canc Netw. 2006 Jul;4(6):583-9.
122.	Lam S, Patel PN. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiol Rev. 2007 May-Jun;15(3):154-61.
123.	Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008 Feb 15;177(4):396-401. Epub 2007 Nov 29.
124.	Laviolette L, Bourbeau J, Bernard S, Lacasse Y, Pepin V, Breton MJ, Baltzan M, Rouleau M, Maltais F. Assessing the impact of pulmonary rehabilitation on functional status in COPD. Thorax. 2008 Feb;63(2):115-21. Epub 2007 Sep 27.
125.	Leeman RF, Huffman CJ, O'Malley SS. Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review. Alcohol Alcohol. 2007 May-Jun;42(3):196-206.
126.	Le Foll B, George TP. Treatment of tobacco dependence: integrating recent progress into practice. CMAJ. 2007 Nov 20;177(11):1373-80.
127.	Lightowler J V, Wedzicha J A, Elliott M W, Ram F S. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis (Brief record). BMJ 2003; 326:185-187
128.	Lopez CM, House-Fancher MA.Management of atrial fibrillation in patients with chronic obstructive pulmonary disease. J Cardiovasc Nurs 2005 Mar-Apr;20(2):133-40
129.	Louw C, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbroker D, Bardin PG. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration. 2007;74(4):411-7. Epub 2006 Sep 5
130.	Luker KA, Chalmers KI, Caress AL, Salmon MP. Smoking cessation interventions in chronic obstructive pulmonary disease and the role of the family: a systematic literature review. J Adv Nurs. 2007 Sep;59(6):559-68
131.	Lusuardi M, Garuti G, Massobrio M, Spagnolatti L, Bendinelli S. Heart and lungs in COPD. Close friends in real life--separate in daily medical practice? Monaldi Arch Chest Dis. 2008 Mar;69(1):11-7.
132.	Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest 2006;130:640-646
133.	MacIntyre NR. Corticosteroid therapy and chronic obstructive pulmonary disease. Respir Care 2006;51(3):289-96
134.	Maurer P, Bachmann MF. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs. 2007 Nov;16(11):1775-83.
135.	McCord JK, Borzak S, Davis T, Gheorghiade M. Usefulness of intravenous magnesium for multifocal atrial tachycardia in patients with chronic obstructive pulmonary disease. Am J Cardiol 1998 Jan 1;81(1):91-3
136.	McCrory DC, Brown C, Gray RN, Goslin RE, Kolimaga JT, MacIntyre NR, Oddone EZ, Matchar DB.  Management of acute exacerbations of chronic obstructive pulmonary disease (Structured Abstract) 2001:256
137.	Meyer P, Menzel M, Muellinger B, Weber N, Haeussinger K, Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. Vaccine 2006 Jul 26;24(31-32):5832-8
138.	Minakata Y, Iijima H, Takahashi T, Miura M, Ogawa H, Kimura K, Koga T, Kinoshita M, Tsuda T, Aizawa H, Ichinose M. Efficacy and safety of formoterol in Japanese patients with COPD. Intern Med. 2008;47(4):217-23. Epub 2008 Feb 15.
139.	Minami S, Kawayama T, Ichiki M, Nishiyama M, Sueyasu Y, Gohara R, Kinoshita M, Koga H, Iwanaga T, Aizawa H. Clinical efficacy of the transdermal tulobuterol patch in patients with chronic obstructive pulmonary disease: a comparison with slow-release theophylline. Intern Med. 2008;47(6):503-9. Epub 2008 Mar 17.
140.	Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother. 2008 Jul;9(10):1755-72.
141.	Mitrouska I, Bouloukaki I, Siafakas NM. Pharmacological approaches to smoking cessation. Pulm Pharmacol Ther. 2007;20(3):220-32. Epub 2006 Feb 23.
142.	Mojon P. Oral health and respiratory infection. J Can Dent Assoc 2002;68(6):340-5
143.	Mokhlesi B. Clinical implications of gastroesophageal reflux disease and swallowing dysfunction in COPD. Am J Respir Med 2003;2(2):117-21
144.	Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother. 2006 Jul;6(7):965-81.
145.	Moro L, Pedone C, Scarlata S, Malafarina V, Fimognari F, Antonelli-Incalzi R. Endothelial dysfunction in chronic obstructive pulmonary disease. Angiology. 2008 Jun-Jul;59(3):357-64. Epub 2008 Apr 2.
146.	Myers T. The value of care algorithms. Pharmacotherapy. 2006 Sep;26(9 Pt 2):181S-91S; discussion 191S-92S
147.	Nides M, Leischow S, Sarna L, Evans SE. Maximizing smoking cessation in clinical practice: pharmacologic and behavioral interventions. Prev Cardiol. 2007 Spring;10(2 Suppl 1):23-30.
148.	NIH State-of-the-Science Conference Statement on Tobacco Use: Prevention, Cessation, and Control. NIH Consens State Sci Statements. 2006 Jun 12-14;23(3):1-26.
149.	Nishimura K, Oga T, Ikeda A, Hajiro T, Tsukino M, Koyama H. Comparison of health-related quality of life measurements using a single value in patients with asthma and chronic obstructive pulmonary disease. J Asthma. 2008 Sep;45(7):615-20.
150.	Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc. 2007 May;82(5):575-82
151.	Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006 Jan;34(1):121-30. Epub 2005 Oct 12.
152.	O’Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax 2006;61(4):354-61
153.	Oh H, Seo W. Meta-analysis of the effects of respiratory rehabilitation programmes on exercise capacity in accordance with programme characteristics. J Clin Nurs. 2007 Jan;16(1):3-15
154.	Ohno Y, Iwasawa T, Seo JB, Koyama H, Takahashi H, Oh YM, Nishimura Y, Sugimura K. Oxygen-enhanced magnetic resonance imaging versus computed tomography: multicenter study for clinical stage classification of smoking-related chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 May 15;177(10):1095-102. Epub 2008 Feb 14.
155.	Okamoto LJ. Outcomes and humanistic issues related to treatment of acute bronchospasm. Pharmacotherapy. 2006 Sep;26(9 Pt 2):175S-80S
156.	Okuyemi KS, Nollen NL, Ahluwalia JS. Interventions to facilitate smoking cessation. Am Fam Physician. 2006 Jul 15;74(2):262-71.
157.	Oncken C, Watsky E, Reeves K, Anziano R. Efficacy and safety of the novel selective nicotinic receptor partial agonist varenicline for smoking cessation. Journal of the American College of Cardiology 2005; 45(3 Suppl A): 381A
158.	Oncken C, Watsky E, Reeves K, Anziano R. Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: results from a Phase 2 study. Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic 2005
159.	Oncken C, Watsky E, Reeves K, Anziano R. Varenicline is efficacious and well tolerated in promoting smoking cessation: results from a 7-week, randomized, placebo- and bupropion-controlled trial. Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic 2005
160.	Padula CA, Yeaw E. Inspiratory muscle training: integrative review. Res Theory Nurs Pract. 2006 Winter;20(4):291-304
161.	Padula CA, Yeaw E. Inspiratory muscle training: integrative review of use in conditions other than COPD.Res Theory Nurs Pract. 2007;21(2):98-118
162.	Pierson DJ. Clinical practice guidelines for chronic obstructive pulmonary disease: a review and comparison of current resources. Respir Care 2006;51(3):277-88
163.	Pisinger C, Godtfredsen NS. Is there a health benefit of reduced tobacco consumption? A systematic review. Nicotine Tob Res. 2007 Jun;9(6):631-46.
164.	Pitta F, Troosters T, Probst VS, Langer D, Decramer M, Gosselink R. Are patients with COPD more active after pulmonary rehabilitation? Chest. 2008 Aug;134(2):273-80. Epub 2008 Apr 10
165.	Polley L, Yaman N, Heaney L, Cardwell C, Murtagh E, Ramsey J, Macmahon J, Costello RW, McGarvey L. Impact of cough across different chronic respiratory diseases: comparison of two cough-specific health-related quality of life questionnaires. Chest. 2008 Aug;134(2):295-302. Epub 2007 Dec 10.
166.	Poole P J, Black P N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review (Brief record). BMJ 2001; 322: 1271-1274
167.	Potts LA, Garwood CL. Varenicline: the newest agent for smoking cessation. Am J Health Syst Pharm. 2007 Jul 1;64(13):1381-4.
168.	Puhan MA, Schünemann HJ, Buesching G, vanOort E, Spaar A, Frey M. COPD patients' ability to follow exercise influences short-term outcomes of rehabilitation. Eur Respir J. 2008 Feb;31(2):304-10. Epub 2007 Nov 7.
169.	Puhan MA, Schunemann HL, Frey M, Bachmann LM. Value of supplemental interventions to enhance the effectiveness of physical exercise during respiratory rehabilitation in COPD patients: a systematic review (Provisional record). Respiratory Research 2004;5:25
170.	Putt MT, Watson M, Seale H, Paratz JD. Muscle stretching technique increases vital capacity and range of motion in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008 Jun;89(6):1103-7
171.	Qaseem A, Snow V, Shekelle P, Sherif K, Wilt TJ, Weinberger S, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007 Nov 6;147(9):633-8.
172.	Ram FSF, Barnes NC, Granados-Navarrete A, Garcia-Aymerich J, Sestini P, Melani AS, Rodriguez-Roisin R. Comparing antibiotics for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews: Protocols 2008 Issue 2 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD007093
173.	Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006 Dec 5;145(11):845-56. Epub 2006 Sep 5.
174.	Reeves KR, Watsky E, Williams KE, Azoulay S, Billing CB, Gong J. The safety of varenicline in cigarette smokers following a 52-week treatment period (RPOS 3-54). Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida 2006: 15
175.	Reid RD, Quinlan B, Riley DL, Pipe AL. Smoking cessation: lessons learned from clinical trial evidence. Curr Opin Cardiol. 2007 Jul;22(4):280-5.
176.	Reus VI, Obach RS, Coe JW, Faessel H, Rollema H, Watsky E, Reeves K. Varenicline: new treatment with efficacy in smoking cessation. Drugs Today (Barc). 2007 Feb;43(2):65-75.
177.	Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease.Respir Care. 2007 Jul;52(7):833-51
178.	Rice KL, Leimer I, Kesten S, Niewoehner DE. Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease. Transl Res. 2008 Aug;152(2):88-94. Epub 2008 Jun 23.
179.	Robert D, Argaud L. Clinical review: long-term noninvasive ventilation. Crit Care. 2007;11(2):210.
180.	Rogers AV, Adelroth E, Hattotuwa K, Dewar A, Jeffery PK. Bronchial mucosal dendritic cells in smokers and ex-smokers with COPD: an electron microscopic study. Thorax. 2008 Feb;63(2):108-14. Epub 2007 Sep 17.
181.	Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007 Mar;52(3):985-94. Epub 2006 Dec 8.
182.	Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007 Jul;28(7):316-25. Epub 2007 Jun 18.
183.	Rutten FH, Vonken EJ, Cramer MJ, Moons KG, Velthuis BB, Prakken NH, Lammers JW, Grobbee DE, Mali WP, Hoes AW. Cardiovascular magnetic resonance imaging to identify left-sided chronic heart failure in stable patients with chronic obstructive pulmonary disease. Am Heart J. 2008 Sep;156(3):506-12. Epub 2008 Jun 17.
184.	Salpeter S R, Ormiston T M, Salpeter E E, Poole P J, Cates C J. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis (Brief record). Respiratory Medicine 2003;97(10):1094-1101
185.	Sanabria A, Valdiviesco E, Gomez G, Echeverry G. Prophylactic antibiotics in chest trauma: a meta-analysis of high-quality studies. World J Surg 2006;30(10):1843-7
186.	Schmier JK, Halpern MT, Jones ML. Effects of inhaled corticosteroids on mortality and hospitalisation in elderly asthma and chronic obstructive pulmonary disease patients: appraising the evidence (Provisional record). Drugs and Aging 2005;22(9):717-719
187.	Schnoll RA, Patterson F, Lerman C. Treating tobacco dependence in women. J Womens Health (Larchmt). 2007 Oct;16(8):1211-8.
188.	Sekine Y, Kesler KA, Behnia M, Brooks-Brunn J, Sekine E, Brown JW. COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer. Chest 2001 Dec;120(6):1783-90
189.	Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 1990 Sep;98(3):672-8
190.	Shetty R, Seddighzadeh A, Piazza G, Goldhaber SZ. Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. J Thromb Thrombolysis. 2008 Aug;26(1):35-40. Epub 2007 Oct 17.
191.	Shukla VK, Husereau DR, Boucher M, Mensinkai S, Dales R. Long-acting beta2-agonists for maintenance therapy of stable chronic obstructive pulmonary disease: a systematic review. (Structured Abstract) 2002:39
192.	Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie RL, Williams D, Gan WQ, Rousseau R; ABC(Advair, Biomarkers in COPD) Investigators. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1207-14. Epub 2008 Feb 28.
193.	Singh SJ, Jones PW, Evans R, Morgan MD. Minimum clinically important improvement for the incremental shuttle walking test. Thorax. 2008 Sep;63(9):775-7. Epub 2008 Apr 4.
194.	Siu EC, Tyndale RF. Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol. 2007;47:541-64.
195.	Smith J, Woodcock A. Cough and its importance in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(3):305-14
196.	Sobieraj DM, White CM, Coleman CI. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Clin Ther. 2008 Aug;30(8):1416-25.
197.	Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease,chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006 Jan;31(1):58-69
198.	Soriano JB, Sin DD, Zhang X, Camp PG, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Petersson S, Postma DS, Szafranski W, Vestbo J. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest. 2007 Mar;131(3):682-9
199.	Spencer S, Evans D. Inhaled corticosteroids versus long acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews: Protocols 2008 Issue 2 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD007033
200.	Spencer LM, Alison JA, McKeough ZJ. Six-minute walk test as an outcome measure: are two six-minute walk tests necessary immediately after pulmonary rehabilitation and at three-month follow-up? Am J Phys Med Rehabil. 2008 Mar;87(3):224-8.
201.	Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge MR. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2008 Mar;63(3):194-200. Epub 2007 Sep 27.
202.	Stack NM. Smoking cessation: an overview of treatment options with a focus on varenicline. Pharmacotherapy. 2007 Nov;27(11):1550-7.
203.	Stead LF, Lancaster T. Nicobrevin for smoking cessation. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005990.
204.	Steele BG, Belza B, Cain KC, Coppersmith J, Lakshminarayan S, Howard J, Haselkorn JK. A randomized clinical trial of an activity and exercise adherence intervention in chronic pulmonary disease. Arch Phys Med Rehabil. 2008 Mar;89(3):404-12.
205.	Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease--the effect of ongoing, systemic steroid treatment. Vaccine 2006 Feb 27;24(9):1408-12
206.	Stoloff S, Samuels S, Kerney D, Brown CP. Management of chronic obstructive pulmonary disease associated with chronic bronchitis with inhaled fluticasone propionate/salmeterol (ADVAIR DISKUS) 250/50: results of a patient experience trial. MedGenMed. 2006 Mar 29;8(1):86
207.	Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J, Mueller B, Tamm M, Mueller C. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest. 2008 May;133(5):1088-94. Epub 2008 Mar 13.
208.	Stull DE, Leidy NK, Jones PW, Ståhl E. Measuring functional performance in patients with COPD: a discussion of patient-reported outcome measures. Curr Med Res Opin. 2007 Nov;23(11):2655-65.
209.	Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006 Dec;3(4):195-202
210.	Swartz S, Gonzales D, Billing CB, Watsky E, Gong J, Williams K, Reeves K. The effect of nicotine dependence level on quit outcomes with varenicline: results from a pooled-analysis of controlled trials (PA11-1). Society for Research on Nicotine and Tobacco 13th Annual Meeting February 21-24, Austin, Texas 2007:3
211.	Taylor AH, Ussher MH, Faulkner G. The acute effects of exercise on cigarette cravings, withdrawal symptoms, affect and smoking behaviour: a systematic review. Addiction. 2007 Apr;102(4):534-43.
212.	Taylor NF, Dodd KJ, Shields N, Bruder A. Therapeutic exercise in physiotherapy practice is beneficial: a summary of systematic reviews 2002-2005. Aust J Physiother. 2007;53(1):7-16
213.	Thabut G, Christie JD, Ravaud P, Castier Y, Brugière O, Fournier M, Mal H, Lesèche G, Porcher R. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet. 2008 Mar 1;371(9614):744-51
214.	Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, Mathur V. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol. 2008 May-Jun;15(3):319-28. Epub 2008 Apr 14.
215.	Tinker R, While A. Promoting quality of life for patients with moderate to severe COPD. Br J Community Nursing 2006;11(7):278-84
216.	Tong EK, Carmody TP, Simon JA. Bupropion for smoking cessation: a review. Compr Ther. 2006 Spring;32(1):26-33.
217.	Tonstad S. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist. J Cardiovasc Nurs. 2006 Nov-Dec;21(6):433-6.
218.	Tonstad S. Varenicline for smoking cessation. Expert Rev Neurother. 2007 Feb;7(2):121-7.
219.	Travers J, Marsh S, Caldwell B, Williams M, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. External validity of randomized controlled trials in COPD. Respir Med. 2007 Jun;101(6):1313-20. Epub 2006 Nov 17
220.	Tsai YH, Lee CJ, Lan RS, Lee CH. Multifocal atrial tachycardia as a prognostic indicator in patients with severe chronic obstructive pulmonary disease requiring mechanical ventilation. Changgeng Yi Xue Za Zhi 1991 Sep;14(3):163-7
221.	Tukek T, Yildiz P, Akkaya V, Karan MA, Atilgan D, Yilmaz V, Korkut F. Factors associated with the development of atrial fibrillation in COPD patients: the role of P-wave dispersion. Ann Noninvasive Electrocardiol 2002 Jul;7(3):222-7
222.	Ueng KC, Lee SH, Wu DJ, Lin CS, Chang MS, Chen SA. Radiofrequency catheter modification of atrioventricular junction in patients with COPD and medically refractory multifocal atrial tachycardia. Chest 2000 Jan;117(1):52-9
223.	Urbano FL, Pasqual RM. Contemporary issues in the care of patients with chronic obstructive pulmonary disease. J Manag Care Pharm 2005;11(5 Suppl A):S2-13; quiz S14-6
224.	Uronis HE, McCrory DC, Samsa GP, Currow DC, Abernethy AP. Palliative oxygen for non-hypoxaemic chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews: Protocols 2007 Issue 2 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD006429
225.	van den Bemt L, Schermer T, Smeele I, Bischoff E, Jacobs A, Grol R, van Weel C. Monitoring of patients with COPD: a review of current guidelines' recommendations. Respir Med. 2008 May;102(5):633-41. Epub 2008 Jan 31.
226.	van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, Kingma JH, Sturkenboom MC, Stricker BH. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006 May 8;166(9):1016-20
227.	Varenicline (CHANTIX): a stop-smoking pill. ORL Head Neck Nurs. 2006 Fall;24(4):18-9.
228.	Vidrine JI, Cofta-Woerpel L, Daza P, Wright KL, Wetter DW. Smoking cessation 2: behavioral treatments. Behav Med. 2006 Fall;32(3):99-109.
229.	Wallace LD, Troy KE. Office-based spirometry for early detection of obstructive lung disease. J Am Acad Nurse Pract 2006;18(9):414-21
230.	White RD. Prehospital recognition of multifocal atrial tachycardia: association with acute myocardial infarction. Ann Emerg Med 1992 Jun;21(6):753-6
231.	Whitley HP, Moorman KL. Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine. Pharmacotherapy. 2007 Oct;27(10):1440-5.
232.	Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007 Apr;23(4):793-801.
233.	Williams M, Cafarella P, Olds T, Petkov J, Frith P. The language of breathlessness differentiates between patients with COPD and age-matched adults. Chest. 2008 Sep;134(3):489-96. Epub 2008 May 19.
234.	Williams MV, Huddleston J, Whitford K, DiFrancesco L, Wilson M. Advances in hospital medicine: a review of key articles from the literature. Med Clin North Am 2002 Jul;86(4):797-823
235.	Wilt TJ, Niewoehner D, Kane RL, MacDonald R, Joseph AM. Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res. 2007 Jan;9(1):21-32.
236.	Wise RA, Tashkin DP. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. Am J Med. 2007 Aug;120(8 Suppl 1):S4-13
237.	Wise RA, Tashkin DP. Preventing chronic obstructive pulmonary disease: what is known and what needs to be done to make a difference to the patient? Am J Med. 2007 Aug;120(8 Suppl 1):S14-22.
238.	Yacoub WG, Reisz G. Kicking butts: smoking cessation update. Mo Med. 2007 May-Jun;104(3):260-4.
239.	Zacarias EC, Castro AA, Cendon S. Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review. J Bras Pneumol. 2007 Apr;33(2):152-60.
240.	Zierler-Brown SL, Kyle JA. Oral varenicline for smoking cessation. Ann Pharmacother. 2007 Jan;41(1):95-9. Epub 2006 Dec 26.
241.	Zwar N, Hermiz O, Hasan I, Comino E, Middleton S, Vagholkar S, Marks G. A cluster randomised controlled trial of nurse and GP partnership for care of chronic obstructive pulmonary disease. BMC Pulm Med. 2008 Jun 3;8:8.